ASCO: Brain Tumors, Genetics, and Side Effects

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Correa discusses her work on brain tumors and genetics, and their contribution to adverse side effects.

In this video, Denise Correa, MD, discusses her work on brain tumors and genetics, and their contribution to adverse side effects.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content
Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

PFS, OS Improve With Cilta-Cel in R/R Multiple Myeloma Subgroups

Kristi Rosa
June 2nd 2025
Article

Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

Russ Conroy
June 2nd 2025
Article

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.

Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma

Roman Fabbricatore
June 1st 2025
Article

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.